GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia?

GenSci Singapore and TWi Pharmaceuticals, Inc. (TWi) ,a leading pharmaceutical company, have recently reached a cooperation agreement for the exclusive distribution of Megaxia? (megestrol acetate oral suspension). Under this agreement, TWi authorizes GenSci Singapore as the sole distributor of Megaxia? in mainland China, Hong Kong, Macau, and Singapore, responsible for the marketing and promotion of this product.

The partnership between GenSci and TWi in the field of cancer treatment is anticipated to improve the clinical adoption of Megaxia? within the population affected by AIDS-related cachexia and cancer-associated anorexia/cachexia, thereby enhancing drug accessibility and elevating the quality of life for patients.

About GenSci

Changchun GeneScience Pharmaceuticals Co., Ltd. (GenSci), established in 1997, is a subsidiary of Changchun High-Tech Industries (Group) Co., Ltd. (stock code 000661). As a pioneering genetic engineering pharmaceutical company, GenSci stands as Asia’s largest manufacturing base for recombinant human growth hormone and the world’s exclusive provider of a comprehensive range of recombinant human growth hormone products.

Combining in-house R&D, production, marketing, and medical services, GenSci has successfully established a complete system for the development of innovative drugs and devices. The company is capable of global development of innovative products such as biologics, chemical drugs, special formulations, live biotherapeutic products, medical devices, and medical nutrition products. GenSci provides products and diagnostic and therapeutic services covering the entire health cycle, including disease screening, diagnosis, prevention, treatment, intervention, and rehabilitation, safeguarding patients both in China and worldwide.

In the oncology sector, GenSci has made significant strides with more than ten innovative drugs in its pipeline, and several drugs/indications are in Phase III clinical trials. Camcevi (sub-Q leuprolide therapy in a prefilled, ready-to-inject formulation for every 6 months), the company is expected to submit its first indication application for marketing in 2024. Additionally, GenSci has developed diverse technological platforms including next-generation ADC(antibody-drug conjugate) technology, targeted radionuclide therapy, NK cell enhancement therapy (NKCE), targeted small molecule drugs, and protein long-acting technology, aiming to develop globally competitive innovative tumor treatments.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. (TWi) is a technology-based special pharmaceutical company focusing on the development and commercialization of “Niche Generics” drugs with a regional focus on the US market. Unlike the common generic drugs, developing niche generic drugs require a full array of expertise, including advanced scientific research, process development, patent analysis, regulatory compliances, and market and competition analysis. Since its launch in the U.S. in 2014, TWi’s Megaxia? has become the leading brand of high-concentration megestrol acetate oral suspension in the U.S. market.